Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential

Liu, Leiling; Hu, Jiahui; Liu, Hao; Qin, Hua‐Li; Wang, Chunfang; Gui, Yajun; Xu, Danyan

doi:10.1007/s10557-023-07463-y

Cited by 4 publications

(2 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transcription factors play a critical role in the progression of myocardial changes, including hypertrophy, fibrosis, genetic cardiomyopathy, and neonatal posthypoxic hypertrophic cardiomyopathy. Recently, many studies have demonstrated the potential to regulate gene expression signaling pathways [1][2][3]. Expression of transcription-activating genes plays a critical role in the myocardium, not only in cardiac hypertrophy but also in intrauterine cardiac differentiation and valve formation [4,5].…”

Section: Introductionmentioning

confidence: 99%

Combined Pharmacological Modulation of Translational and Transcriptional Activity Signaling Pathways as a Promising Therapeutic Approach in Children with Myocardial Changes

Kamenshchyk,

Belenichev,

Oksenych

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Myocardial hypertrophy is the most common condition that accompanies heart development in children. Transcriptional gene expression regulating pathways play a critical role both in cardiac embryogenesis and in the pathogenesis of congenital hypertrophic cardiomyopathy, neonatal posthypoxic myocardial hypertrophy, and congenital heart diseases. This paper describes the state of cardiac gene expression and potential pharmacological modulators at different transcriptional levels. An experimental model of perinatal cardiac hypoxia showed the downregulated expression of genes responsible for cardiac muscle integrity and overexpressed genes associated with energy metabolism and apoptosis, which may provide a basis for a therapeutic approach. Current evidence suggests that RNA drugs, theaflavin, neuraminidase, proton pumps, and histone deacetylase inhibitors are promising pharmacological agents in progressive cardiac hypertrophy. The different points of application of the above drugs make combined use possible, potentiating the effects of inhibition in specific signaling pathways. The special role of N-acetyl cysteine in both the inhibition of several signaling pathways and the reduction of oxidative stress was emphasized.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined Pharmacological Modulation of Translational and Transcriptional Activity Signaling Pathways as a Promising Therapeutic Approach in Children with Myocardial Changes

Kamenshchyk,

Belenichev,

Oksenych

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Basic genes regulating these reactions belong to the nuclear factor-activated T-cell family (NFATC) with the highest expression in adipocytes, chondrocytes, and during the morphogenesis of veins and heart valves, as well as in myocardial hypertrophy [ 6 , 7 ]. In addition, the recruitment of T cells in myocardial remodeling and heart failure has been demonstrated [ 8 , 9 ]. Homozygous alleles with conservative sequences of the NFATC1 gene were found in 1 out of 4 patients with BAV [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Association of Myocardial Changes and Gene Expression of the NFATC1 and NFATC4—Calcineurin Signaling Pathway in Children with Bicuspid Aortic Valve

Kamenshchyk,

Gonchar,

Oksenych

et al. 2023

Children

View full text Add to dashboard Cite

Background: The role of NFATC gene expression in bicuspid aortic valve (BAV) progression is not fully understood. The aim of this study is to determine the significance of NFATC1 and NFATC4 gene expression for myocardial changes in children with BAV. Methods: In 47 children with BAV, the standard Doppler echocardiographic characteristics were detected, and the expression of the NFATC1 and NFATC4 genes was studied. Results: Posterior wall thickness in diastole (PWTd) and aortic valve peak pressure gradient (AoPPG) in BAV patients were significantly higher compared to healthy controls (PWTd median (min–max), 9 (7–10) mm vs. 7 (6–8) mm; and AoPPG median (min–max), 7.79 (2.98–15.09) mm Hg vs. 2.94 (2.42–3.72) mm Hg). The expression of the NFATC1 gene in BAV children was significantly higher compared to NFATC4 (NFATC1 median (min–max); 70.88 (8.79–106.51) e.u. vs. 7.72 (1.74–22.67) e.u., respectively p < 0.05). A significant correlation of NFATC1 expression with Ao found (R = +0.53, p < 0.05). In BAV patients with PWTd > 8 mm and Ao > 21 mm the NFATC1 expression was significantly higher compared to those with PWTd ≤ 8 mm and Ao ≤ 21 mm (NFATC1 median (min–max); 45.49 (5.01–101.52) e.u. vs. 15.53 (2.36–44.40) e.u., p < 0.05 and 81.11 (20.27–101.10) e.u. mm vs. 12.16 (2.40–45.49) e.u., p < 0.05, respectively). Conclusion: In children with BAV the high expression of the NFATC1 calcineurin signaling pathway gene is associated with elevated PWTd and Ao.

show abstract

Isoprenaline Inhibits Histone Demethylase LSD1 to Induce Cardiac Hypertrophy

Wu,

Yang,

Sun

et al. 2024

Cardiovasc Toxicol

View full text Add to dashboard Cite

Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential

Cited by 4 publications

References 144 publications

Combined Pharmacological Modulation of Translational and Transcriptional Activity Signaling Pathways as a Promising Therapeutic Approach in Children with Myocardial Changes

Combined Pharmacological Modulation of Translational and Transcriptional Activity Signaling Pathways as a Promising Therapeutic Approach in Children with Myocardial Changes

Association of Myocardial Changes and Gene Expression of the NFATC1 and NFATC4—Calcineurin Signaling Pathway in Children with Bicuspid Aortic Valve

Isoprenaline Inhibits Histone Demethylase LSD1 to Induce Cardiac Hypertrophy

Contact Info

Product

Resources

About